Achilles Therapeutics Plc Stock Filter Stocks by Fundamentals
| ACHL Stock | USD 1.12 0.01 0.88% |
Achilles Therapeutics PLC fundamentals help investors to digest information that contributes to Achilles Therapeutics' financial success or failures. It also enables traders to predict the movement of Achilles Stock. The fundamental analysis module provides a way to measure Achilles Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Achilles Therapeutics stock.
Achilles | Shares Owned by Institutions |
Achilles Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Achilles Therapeutics from analyzing Achilles Therapeutics' financial statements. These drivers represent accounts that assess Achilles Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Achilles Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 672.3M | 143.6M | 35.2M | 35.5M | 40.9M | 38.8M | |
| Enterprise Value | 510.4M | (110.5M) | (129.5M) | (91.4M) | (105.1M) | (99.8M) |
Achilles Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Achilles Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Achilles Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Achilles Therapeutics' value.| Shares | Two Sigma Investments Llc | 2024-09-30 | 21.2 K | Corsair Capital Management Llc | 2024-09-30 | 20 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 16.4 K | Baader Bank Inc | 2024-09-30 | 14.2 K | Susquehanna International Group, Llp | 2024-09-30 | 12.4 K | Brave Asset Management Inc | 2024-09-30 | 10 K | Rhumbline Advisers | 2024-09-30 | 4.5 K | Arcadia Investment Management Corp | 2024-09-30 | 3 K | Jpmorgan Chase & Co | 2024-09-30 | 137 | Syncona Portfolio Ltd. | 2024-09-30 | 11.1 M | Bml Capital Management Llc | 2024-09-30 | 4.1 M |
Achilles Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (34.59 M) | ||||
| Shares Outstanding | 41.1 M | ||||
| Shares Owned By Insiders | 6.51 % | ||||
| Shares Owned By Institutions | 59.29 % | ||||
| Number Of Shares Shorted | 122.36 K | ||||
| Price To Earning | 0.49 X | ||||
| Price To Book | 0.45 X | ||||
| EBITDA | (70.44 M) | ||||
| Net Income | (69.94 M) | ||||
| Cash And Equivalents | 201.6 M | ||||
| Cash Per Share | 4.94 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.45 X | ||||
| Book Value Per Share | 3.46 X | ||||
| Cash Flow From Operations | (48.45 M) | ||||
| Short Ratio | 1.69 X | ||||
| Earnings Per Share | (1.66) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 0.5 | ||||
| Number Of Employees | 204 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 47.84 M | ||||
| Total Asset | 161.46 M | ||||
| Retained Earnings | (259.95 M) | ||||
| Working Capital | 128.64 M | ||||
| Net Asset | 161.46 M |
About Achilles Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Achilles Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Achilles Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Achilles Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Achilles Therapeutics Piotroski F Score and Achilles Therapeutics Altman Z Score analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.